{
    "root": "35063fad-e644-2b68-e063-6394a90aedc8",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Sulfamethoxazole and Trimethoprim",
    "value": "20250513",
    "ingredients": [
        {
            "name": "CITRIC ACID MONOHYDRATE",
            "code": "2968PHW8QP"
        },
        {
            "name": "SODIUM BENZOATE",
            "code": "OJ245FE5EU"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "METHYLPARABEN",
            "code": "A2I8C7HI9T"
        },
        {
            "name": "CARBOXYMETHYLCELLULOSE SODIUM, UNSPECIFIED FORM",
            "code": "K679OBS311"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "SACCHARIN SODIUM",
            "code": "SB8ZUX40TY"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX"
        },
        {
            "name": "ALCOHOL",
            "code": "3K9958V90M"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "SORBITOL",
            "code": "506T60A25R"
        },
        {
            "name": "SULFAMETHOXAZOLE",
            "code": "JE42381TNV"
        },
        {
            "name": "TRIMETHOPRIM",
            "code": "AN164J8Y0X"
        }
    ],
    "indications": "reduce development drug-resistant bacteria maintain eﬀectiveness sulfamethoxazole trimethoprim antibacterial drugs , sulfamethoxazole trimethoprim used treat prevent infections proven strongly suspected caused susceptible bacteria . culture susceptibility information available , considered selecting modifying antibacterial therapy . absence data , local epidemiology susceptibility patterns may contribute empiric selection therapy . urinary tract infections treatment urinary tract infections due susceptible strains following organisms : escherichia coli , klebsiella species , enterobacter species , morganella morganii , proteus mirabilis proteus vulgaris . recommended initial episodes uncomplicated urinary tract infections treated single eﬀective antibacterial agent rather combination . acute otitis media treatment acute otitis media pediatric patients due susceptible strains streptococcus pneumoniae haemophilus influenzae judgment physician sulfamethoxazole trimethoprim oﬀers advantage antimicrobial agents . date , limited data safety repeated sulfamethoxazole trimethoprim pediatric patients two years age . sulfamethoxazole trimethoprim indicated prophylactic prolonged otitis media age . acute exacerbations chronic bronchitis adults treatment acute exacerbations chronic bronchitis due susceptible strains streptococcus pneumoniae haemophilus influenzae physician deems sulfamethoxazole trimethoprim could oﬀer advantage single antimicrobial agent . shigellosis treatment enteritis caused susceptible strains shigella flexneri shigella sonnei antibacterial therapy indicated . pneumocystis jirovecii pneumonia treatment documented pneumocystis jirovecii pneumonia prophylaxis p. jirovecii pneumonia individuals immunosuppressed considered increased risk developing p. jirovecii pneumonia . traveler ’ diarrhea adults treatment traveler ’ diarrhea due susceptible strains enterotoxigenic e. coli .",
    "contraindications": "sulfamethoxazole trimethoprim contraindicated pediatric patients less 2 months age . urinary tract infections shigellosis adults pediatric patients , acute otitis media children adults : usual adult treatment urinary tract infections 4 teaspoonfuls ( 20 ml ) sulfamethoxazole trimethoprim every 12 hours 10 14 days . identical daily used 5 days treatment shigellosis . children : recommended dose children urinary tract infections acute otitis media 40 mg/kg sulfamethoxazole 8 mg/kg trimethoprim per 24 hours , given two divided doses every 12 hours 10 days . identical daily used 5 days treatment shigellosis . following table guideline attainment : children 2 months age older : weight dose - every 12 hours lb kg teaspoonfuls 22 10 1 ( 5 ml ) 44 20 2 ( 10 ml ) 66 30 3 ( 15 ml ) 88 40 4 ( 20 ml ) patients impaired renal function renal function impaired , reduced employed using following table : creatinine clearance ( ml/min ) recommended regimen 30 usual standard regimen 15 - 30 1⁄2 ; usual regimen 15 recommended acute exacerbations chronic bronchitis adults usual adult treatment acute exacerbations chronic bronchitis 4 teaspoonfuls ( 20 ml ) sulfamethoxazole trimethoprim every 12 hours 14 days . pneumocystis jirovecii pneumonia treatment adults children : recommended treatment patients documented pneumocystis jirovecii pneumonia 75 100 mg/kg sulfamethoxazole 15 20 mg/kg trimethoprim per 24 hours given equally divided doses every 6 hours 14 21 days . 12 following table guideline upper limit : weight dose - every 6 hours lb kg teaspoonfuls 18 8 1 ( 5 ml ) 35 16 2 ( 10 ml ) 53 24 3 ( 15 ml ) 70 32 4 ( 20 ml ) 88 40 5 ( 25 ml ) 106 48 6 ( 30 ml ) 141 64 8 ( 40 ml ) 176 80 10 ( 50 ml ) lower limit dose ( 75 mg/kg sulfamethoxazole 15 mg/kg trimethoprim per 24 hours ) administer 75 % dose table . prophylaxis adults : recommended prophylaxis adults 4 teaspoonfuls ( 20 ml ) sulfamethoxazole trimethoprim daily . 13 children : children , recommended dose 750 mg/m 2/day sulfamethoxazole 150 mg/m 2/day trimethoprim given orally equally divided doses twice day , 3 consecutive days per week . total daily dose exceed 1600 mg sulfamethoxazole 320 mg trimethoprim . 14 following table guideline attainment children : body surface area dose - every 12 hours ( 2 ) teaspoonfuls 0.26 1⁄2 ; ( 2.5 ml ) 0.53 1 ( 5 ml ) 1.06 2 ( 10 ml ) traveler ’ diarrhea adults treatment traveler ’ diarrhea , usual adult 4 teaspoonfuls ( 20 ml ) sulfamethoxazole trimethoprim every 12 hours 5 days .",
    "warningsAndPrecautions": "sulfamethoxazole trimethoprim oral suspension usp , supplied pink , syrupy , sour cherry flavored suspension containing 200 mg sulfamethoxazole 40 mg trimethoprim per 5 ml ( teaspoonful ) available follows : ndc 81033-012-20 : 20 ml unit dose cup ndc 81033-012-40 : carton 40 ( 20 ml ) unit dose cups store 20°c 25°c ( 68°f 77°f ) [ usp controlled room temperature ] . protect light . dispense tight , light-resistant container . shake well using . report suspected , contact kesin pharma 1-833-537-4679 fda 1-800-fda-1088 www.fda.gov/medwatch .",
    "adverseReactions": "sulfamethoxazole trimethoprim contraindicated following situations : known hypersensitivity trimethoprim sulfonamides history drug-induced immune thrombocytopenia trimethoprim and/or sulfonamides documented megaloblastic anemia due folate deficiency pediatric patients less 2 months age marked hepatic damage severe renal insufficiency renal function status monitored concomitant dofetilide ( ) .",
    "indications_original": "To reduce the development of drug-resistant bacteria and maintain the eﬀectiveness of sulfamethoxazole and trimethoprim and other antibacterial drugs, sulfamethoxazole and trimethoprim should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy.\n                  \n                  \n                     \n                        Urinary Tract Infections\n                     \n                  \n                  For the treatment of urinary tract infections due to susceptible strains of the following organisms: \n  Escherichia coli, \n  Klebsiella species,\n   Enterobacter species, \n  Morganella morganii, \n  Proteus mirabilis and \n  Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single eﬀective antibacterial agent rather than the combination.\n \n                  \n                  \n                     \n                        Acute Otitis Media\n                     \n                  \n                  For the treatment of acute otitis media in pediatric patients due to susceptible strains of \n  Streptococcus pneumoniae or \n  Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim oﬀers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim are not indicated for prophylactic or prolonged administration in otitis media at any age.\n \n                  \n                  \n                     \n                        Acute Exacerbations of Chronic Bronchitis in Adults\n                     \n                  \n                  For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of \n  Streptococcus pneumoniae or \n  Haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim could oﬀer some advantage over the use of a single antimicrobial agent.\n \n                  \n                  \n                     \n                        Shigellosis\n                     \n                  \n                  For the treatment of enteritis caused by susceptible strains of \n  Shigella flexneri and \n  Shigella sonnei when antibacterial therapy is indicated.\n \n                  \n                  \n                     \n                        \n                           Pneumocystis jirovecii Pneumonia\n   \n                     \n                  \n                  For the treatment of documented \n  Pneumocystis jirovecii pneumonia and for prophylaxis against \n  P. jirovecii pneumonia in individuals who are immunosuppressed and considered to be at an increased risk of developing \n  P. jirovecii pneumonia.\n \n                  \n                  \n                     \n                        Traveler’s Diarrhea in Adults\n                     \n                  \n                  For the treatment of traveler’s diarrhea due to susceptible strains of enterotoxigenic \n  E. coli.",
    "contraindications_original": "Sulfamethoxazole and trimethoprim is contraindicated in pediatric patients less than 2 months of age.\n                  \n                  \n                     \n                        Urinary Tract Infections and Shigellosis in Adults and Pediatric Patients, and Acute Otitis Media in Children\n                     \n                  \n                  \n                  \n                  \n                     Adults: The usual adult dosage in the treatment of urinary tract infections is 4 teaspoonfuls (20 mL) of sulfamethoxazole and trimethoprim every 12 hours for 10 to 14 days. An identical daily dosage is used for 5 days in the treatment of shigellosis.\n \n                  \n                  \n                  \n                     Children: The recommended dose for children with urinary tract infections or acute otitis media is 40 mg/kg sulfamethoxazole and 8 mg/kg trimethoprim per 24 hours, given in two divided doses every 12 hours for 10 days. An identical daily dosage is used for 5 days in the treatment of shigellosis. The following table is a guideline for the attainment of this dosage:\n \n                  \n                  \n                  \n                     Children 2 months of age or older:\n                  \n                  \n                     \n                        \n                           Weight\n                           \n                           Dose - every 12 hours\n                        \n                        \n                           lb\n                           kg\n                           Teaspoonfuls\n                        \n                        \n                           \n                              22 \n                           \n                           10\n                           1 (5 mL)\n                        \n                        \n                           44\n                           20\n                           2 (10 mL)\n                        \n                        \n                           66\n                           30\n                           3 (15 mL)\n                        \n                        \n                           88\n                           40\n                           4 (20 mL)\n                        \n                     \n                  \n                  \n                     \n                        For Patients with Impaired Renal Function\n                     \n                     \nWhen renal function is impaired, a reduced dosage should be employed using the following table:\n \n                  \n                     \n                        \n                           \n                              Creatinine Clearance (mL/min)\n                           \n                           \n                              Recommended Dosage Regimen\n                           \n                        \n                        \n                           Above\n                           30 Usual standard regimen\n                        \n                        \n                           15 - 30\n                           1⁄2; the usual regimen\n                        \n                        \n                           Below 15\n                           Use not recommended\n                        \n                     \n                  \n                  \n                     \n                        Acute Exacerbations of Chronic Bronchitis in Adults\n                     \n                     \nThe usual adult dosage in the treatment of acute exacerbations of chronic bronchitis is 4 teaspoonfuls (20 mL) of sulfamethoxazole and trimethoprim every 12 hours for 14 days.\n \n                  \n                  \n                     \n                        \n                           Pneumocystis jirovecii\n                        \n                         Pneumonia \n                     \n                     \n                        \n                           Treatment\n                        \n                     \n                  \n                  \n                  \n                     Adults and Children:\n                     \nThe recommended dosage for treatment of patients with documented \n  Pneumocystis jirovecii pneumonia is 75 to 100 mg/kg sulfamethoxazole and 15 to 20 mg/kg trimethoprim per 24 hours given in equally divided doses every 6 hours for 14 to 21 days.\n  12\n                     \nThe following table is a guideline for the upper limit of this dosage:\n \n                  \n                     \n                        \n                           \n                              Weight\n                           \n                           \n                              Dose - every 6 hours\n                           \n                        \n                        \n                           lb\n                           kg\n                           Teaspoonfuls\n                        \n                        \n                           18\n                           8\n                           1 (5 mL)\n                        \n                        \n                           35\n                           16\n                           2 (10 mL)\n                        \n                        \n                           53\n                           24\n                           3 (15 mL)\n                        \n                        \n                           70\n                           32\n                           4 (20 mL)\n                        \n                        \n                           88\n                           40\n                           5 (25 mL)\n                        \n                        \n                           106\n                           48\n                           6 (30 mL)\n                        \n                        \n                           141\n                           64\n                           8 (40 mL)\n                        \n                        \n                           176\n                           80\n                           10 (50 mL)\n                        \n                     \n                  \n                  For the lower limit dose (75 mg/kg sulfamethoxazole and 15 mg/kg trimethoprim per 24 hours) administer 75% of the dose in the above table.\n                  \n                     \n                        Prophylaxis\n                     \n                  \n                  \n                     Adults:\n                     \nThe recommended dosage for prophylaxis in adults is 4 teaspoonfuls (20 mL) of sulfamethoxazole and trimethoprim daily.\n  13\n                  \n                  \n                  \n                     Children:\n                     \nFor children, the recommended dose is 750 mg/m\n  2/day sulfamethoxazole with 150 mg/m\n  2/day trimethoprim given orally in equally divided doses twice a day, on 3 consecutive days per week. The total daily dose should not exceed 1600 mg sulfamethoxazole and 320 mg trimethoprim.\n  14\n                     \nThe following table is a guideline for the attainment of this dosage in children:\n \n                  \n                     \n                        \n                           \n                              Body Surface Area\n                           \n                           \n                              Dose - every 12 hours\n                           \n                        \n                        \n                           (m\n     2)\n    \n                           Teaspoonfuls\n                        \n                        \n                           0.26\n                           1⁄2; (2.5 mL)\n                        \n                        \n                           0.53\n                           1 (5 mL)\n                        \n                        \n                           1.06\n                           2 (10 mL)\n                        \n                     \n                  \n                  \n                     \n                        Traveler’s Diarrhea in Adults\n                     \n                     \nFor the treatment of traveler’s diarrhea, the usual adult dosage is 4 teaspoonfuls (20 mL) of sulfamethoxazole and trimethoprim every 12 hours for 5 days.",
    "warningsAndPrecautions_original": "Sulfamethoxazole and Trimethoprim Oral Suspension USP, is supplied in a pink, syrupy, sour cherry flavored suspension containing 200 mg sulfamethoxazole and 40 mg trimethoprim per 5 mL (teaspoonful) and available as follows:\n                  \n                  NDC 81033-012-20: 20 mL unit dose cup\n                  NDC 81033-012-40: Carton of 40 (20 mL) unit dose cups each\n                  \n                  \n                  Store at 20°C to 25°C (68°F to 77°F) [See USP Controlled Room Temperature].\n                  \n                  \n                  Protect from light.\n                  \n                  \n                  DISPENSE IN TIGHT, LIGHT-RESISTANT CONTAINER.\n                  \n                  \n                  Shake well before using.\n                  \n                  \n                  \n                  \n                     To report SUSPECTED ADVERSE REACTIONS, contact Kesin Pharma at 1-833-537-4679 or FDA at 1-800-FDA-1088 or\n   \n                        www.fda.gov/medwatch.",
    "adverseReactions_original": "Sulfamethoxazole and trimethoprim is contraindicated in the following situations:\n                  \n                     known hypersensitivity to trimethoprim or sulfonamides\n                     history of drug-induced immune thrombocytopenia with use of trimethoprim and/or sulfonamides\n                     documented megaloblastic anemia due to folate deficiency\n                     pediatric patients less than 2 months of age\n                     marked hepatic damage\n                     severe renal insufficiency when renal function status cannot be monitored\n                     concomitant administration with dofetilide (see \n   PRECAUTIONS)."
}